MorphoSys AG (MOR)

NASDAQ: MOR · IEX Real-Time Price · USD
18.14
0.00 (0.00%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States.

The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.

It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.

The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

MorphoSys AG
MorphoSys AG logo
Country Germany
Founded 1992
IPO Date Mar 9, 1999
Industry Biotechnology
Sector Healthcare
Employees 524
CEO Dr. Jean-Paul Kress M.D.

Contact Details

Address:
Semmelweisstr. 7
Planegg, 2M 82152
Germany
Phone 49 89 89927-0
Website morphosys.com

Stock Details

Ticker Symbol MOR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001340243
CUSIP Number 617760202
ISIN Number US6177602025
SIC Code 2834

Key Executives

Name Position
Dr. Jean-Paul Kress M.D. Chairman of Management Board, MD and Chief Executive Officer
Dr. Lucinda Crabtree Ph.D. Chief Financial Officer and Member of Management Board
Charlotte Lohmann Chief Legal and Human Resources Officer and Member of Management Board
Klaus De Wall Head of Accounting and Tax
Dr. Margit Urban Head of Discovery Alliances and Technologies
Dr. Julia Neugebauer Ph.D. Head of Investor Relations
Dr. Barbara Krebs-Pohl Ph.D. Chief Business Officer
Dr. Günter Wellnhofer Head of Technical Operations
Dr. Harald Watzka Head of Alliance Management
Yen Ching Chua Head of Clinical Operations

Latest SEC Filings

Date Type Title
Mar 27, 2024 6-K Report of foreign issuer
Mar 26, 2024 6-K Report of foreign issuer
Mar 25, 2024 6-K Report of foreign issuer
Mar 22, 2024 SC14D9C Filing
Mar 22, 2024 6-K Report of foreign issuer
Mar 22, 2024 6-K Report of foreign issuer
Mar 21, 2024 6-K Report of foreign issuer
Mar 20, 2024 6-K Report of foreign issuer
Mar 20, 2024 6-K Report of foreign issuer
Mar 19, 2024 6-K Report of foreign issuer